New multivariate and univariate methods were developed for the analysis of two novel gliptin combinations by manipulating the zero-order and ratio spectra of empagliflozin and linagliptin in combination, with application on Glyxambi® tablets, and of alogliptin and pioglitazone in combination, with application on Oseni® tablets. Linearity ranges for chemometric approaches using principal component regression and partial least-squares were found to be 2-10, 2.5-12.5, 5-15, and 5-25 μg/mL for empagliflozin, linagliptin, alogliptin, and pioglitazone, respectively, whereas the respective linearity ranges for the spectrophotometric approaches were found to be 5-15, 2-12, 5-15, and 5-15 μg/mL. The proposed spectrophotometric methods included ratio subtraction coupled with extended ratio subtraction, spectrum subtraction coupled with constant multiplication, and mean centering. Acceptable LOD and LOQ values were obtained by all methods. Statistical analysis showed no significant difference between multivariate and univariate methods in comparison with the reference methods. The optimized methods provide fast and economic determination of the recently approved antidiabetic combinations without the complex instrumentation or time-consuming mobile phase preparations that were used in the chromatographic techniques reported in the literature.